Li Ka-Shing’s Horizon Ventures co-leads $40m round in infant probiotic firm Evolve Evolve BioSystems' flagship infant probiotic product Evivo. Photo from company website. Mars Woo June 14, 2018 PremiumHorizon Ventures, the private investment arm of Hong Kong-based billionaire Li Ka-shing, has co-led a $40-million Series C funding round in US-based infant gut microbiome company Evolve BioSystems. Continue reading this story with a subscription to DealStreetAsia. Subscribe Already a subscriber? Log in Should your colleagues be reading this article too? Contact us for corporate subscriptions at firstname.lastname@example.org.